Cambridge Healthtech Institute’s 12th Annual
Engineering Cell Therapies
Unleashing the Power of Smarter Cell Therapies
May 13-14, 2025
Cambridge Healthtech Institute’s 12th Annual Engineering Cell Therapies conference focuses on the latest engineering strategies driving the development of adoptive and innate cell therapies against cancer and immune disorders, such as CAR Ts, TCR-Ts, TILs, CAR-Ms, NKs. Topics include: novel engineering, targeting solid tumors, cell therapies for autoimmune disorders, gene editing, synthetic biology, off-the-shelf approaches, and improving overall safety and efficacy. All supported by lessons learned from preclinical and clinical development.
Coverage will include, but is not limited to:
- Cell therapies for solid tumors
- Cellular therapies for autoimmune disease
- Gene engineering, synthetic circuits, logic gates, switches, prime, base editing
- Emerging targets, novel constructs
- Off-the-shelf approaches
- CAR Ts in combination with other modalities
- Advances in CAR-NKs, CAR-Macrophages, RNA Cell Therapies, T Regs, Gamma deltas
- NK for Solid Tumors, NK Cell Engagers
- TILs—beyond first generation
- Mitigating toxicity and resistance
- FDA feedback
- Improving patient response to cell therapies
- Developability and manufacturability
The deadline for priority consideration is October 11, 2024.
AAll proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: